The use of imatinib appears to be associated with interstitial lung disease (ILD) in patients with chronic myeloid leukaemia (CML)

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1551, 2006-01, pp. : 22-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Imatinib: A Review of its Use in Chronic Myeloid Leukaemia

By Moen Marit D.   McKeage Kate   Plosker Greg L.   Siddiqui M. Asif A.  

Drugs, Vol. 67, Iss. 2, 2007-01 ,pp. : 299-320

Adis International

Access to resources Recommend Favorite

Imatinib mesylate-resistant cells were present in a man with chronic myeloid leukaemia (CML) before treatment with the drug

By  

Inpharma, Vol. 1, Iss. 1390, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Imatinib mesylate normalised the bone marrow of patients with chronic myeloid leukaemia

By  

Inpharma, Vol. 1, Iss. 1327, 2002-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Dasatinib Treatment for Imatinib Resistant or Intolerant Patients with Chronic Myeloid Leukaemia

By Li J   Xu G   Yu S   He L   Guo L  

The Journal of International Medical Research, Vol. 39, Iss. 2, 2011-03 ,pp. : 337-347

Field House Publishing

Access to resources Recommend Favorite

Drug-induced interstitial lung disease (ILD) associated with statins is a "rare but serious" adverse reaction

By  

Reactions Weekly, Vol. 1, Iss. 1325, 2010-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite